Merck's Keytruda wins FDA 'breakthrough' tag in colorectal cancer; Allergan nabs bowel drug rights in Europe;

> Merck & Co. ($MRK) won the FDA's breakthrough designation for its immuno-oncology therapy Keytruda in colorectal cancer; the drug is already approved to treat melanoma and lung cancer. Release

> Allergan ($AGN) bought the rights to Constella (linaclotide) in 40-plus countries, including major European markets, from Spain's Almirall; the drug is sold as Linzess in the U.S. Report

> New blockbuster drugs will drive big growth in the multiple myeloma market, GlobalData says, to $22.4 billion in sales by 2023, up from $8.9 billion in 2014. Report

> GlaxoSmithKline ($GSK), Roche ($RHHBY) and Sanofi ($SNY) all have major investor presentations this week, highlighting their R&D pipelines, and, in Sanofi's case, a new strategy from its new CEO, Olivier Brandicourt. Report

> Eisai said it's presenting data from an Asian Fycompa study in patients with difficult-to-treat partial-onset seizures, in which the drug topped placebo at cutting the frequency of seizures. Release

And Finally... The Novartis Foundation and its partners launched a hypertension screening effort in Ghana as part of a two-year test of an "innovative healthcare model" designed to control high blood pressure. Release